Event Recap: Regulatory Strategy, Evidence, and Product Decisions
November 19, 2026A regulatory milestone is one part of a product's path to commercial success. The evidence developed along the way also shapes reimbursement, labeling, promotional claims, and the company's ability to explain why its product matters.
That connection was central to “Regulatory Strategy, Evidence, and Product Decisions,” a panel at our Pharma, Medtech, and Biotech: Regulatory Updates, AI Risks, & Enforcement Trends program, held November 12, 2026, in Newport Beach, California. Nathan Downing moderated the discussion with Dr. Cord Willhöft of Fieldfisher, Amanda Johnston of Gardner Law, and Jeffrey Lau of Glaukos.
Plan Studies for the Full Path to Market
The panel urged companies to consider clinical need, regulatory requirements, reimbursement, and commercial positioning together. Johnston captured the practical concern:
“You could build something that works great, but it doesn't get reimbursed.”
Amanda Johnston, Partner
She also discussed a staged approach to indications when an initial submission cannot support everything a company ultimately hopes to achieve. Lau brought the commercial perspective to study design. A company hoping to distinguish its product by how quickly it works, for example, needs evidence that can support that claim.
“Planning that and understanding the market need for the product, I think, is really important at the front end,” Jeffrey Lau said. He described the value of involving commercial colleagues in labeling discussions and maintaining regular communication among regulatory, commercial, intellectual property, and research and development counsel.
Account for Differences Across Markets
Willhöft described how regulatory complexity, clinical evidence expectations, and notified body capacity affect European market planning. He emphasized understanding reimbursement expectations in the countries where a company intends to launch. Evidence sufficient for a CE mark may leave additional questions for reimbursement authorities.
As Dr. Cord Willhöft explained, “you have to involve the regulatory bodies and the notified bodies at the earliest stage possible.” He also discussed how notified bodies' neutrality limits the form of guidance they can provide.
The panel applied the same coordination principle to AI-enabled products, discussing overlapping medical device requirements, AI rules, privacy considerations, and state laws. Downing encouraged companies to develop a consistent explanation of the product and its intended use before approaching regulators.
Evaluate Regulatory Responses in Context
When FDA challenges a company's conduct or claims, Johnston emphasized taking the communication seriously, acting promptly, and assessing whether the company has a supported response. Lau added that the decision should account for broader business priorities and other discussions with FDA. A potentially defensible promotional claim may still require a business judgment about the time and resources involved in pursuing a disagreement.
Practical Takeaways for Product Teams
The discussion identified several priorities for connecting regulatory strategy with commercial objectives:
- Plan clinical evidence around regulatory requirements, reimbursement expectations, and the claims the business hopes to make.
- Involve commercial colleagues early in study design and labeling discussions.
- Assess market-specific requirements and opportunities before committing to a global launch sequence.
- Keep regulatory, legal, compliance, and business teams aligned on the product's intended use and supporting evidence.
- Evaluate responses to regulators in light of the evidence, available resources, and broader company priorities.
Watch the Discussion and Contact Gardner Law
Watch the recording above and download the slides for the full discussion of regulatory strategy and market access. Our attorneys help companies connect regulatory planning with clinical evidence, product claims, and commercial objectives. Contact Gardner Law to discuss the evidence and regulatory questions affecting your product strategy.